CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Organon & Co.

OGN
$3.53B
Mid Cap
NASDAQPharmaceutical PreparationsPharmaceuticals🇺🇸North AmericaJERSEY CITY10.0K employees

Organon & Co. is an American pharmaceutical company originally founded in Oss, The Netherlands and now headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.

Website

Drugs in Pipeline

98

Phase 3 Programs

80

Upcoming Catalysts

1

Next Catalyst

Aug 4, 2026

20d

Market Overview

Stock performance and key metrics

OGN News
Catalyst Timeline

1 upcoming, 0 past

How OGN's past catalysts played out

Drug Pipeline

MK0217, alendronate sodium / Duration of Treatment : 2 Years

Phase 3

Osteoporosis, Postmenopausal

simvastatin

Phase 3

Hypercholesterolemia

montelukast sodium

Phase 3

Seasonal Allergic Rhinitis

ezetimibe (+) simvastatin

Phase 3

Hyperlipidemia

Corifollitropin alfa

Phase 3

In Vitro Fertilization

MK0954, /Duration of Treatment : 16 Weeks

Phase 3

Hypertension

EZ 10 mg/Atorva 20 mg FDC

Phase 3

Hypercholesterolemia

Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID

Phase 3

Asthma

Eptifibatide (Integrilin)

Phase 3

Myocardial Ischemia

MK0462, rizatriptan benzoate / Duration of Treatment -1day

Phase 3

Migraine

loratadine; montelukast

Phase 3

Rhinitis, Allergic, Seasonal

MK0476, montelukast sodium

Phase 3

Rhinitis, Allergic, Seasonal

Rescue medication

Phase 3

Bipolar Disorder

alendronate

Phase 3

Paget's Disease of Bone

Atorvastatin 10 mg

Phase 3

Hypercholesterolemia

Asenapine 5 mg

Phase 3

Schizophrenia

MK-0954A

Phase 3

Hypertension

ibandronate

Phase 3

Postmenopausal Osteoporosis

MK0954, /Duration of Treatment : 5 Years

Phase 3

Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart)

MK0906, finasteride / Duration of Treatment: 48 weeks

Phase 3

Benign Prostatic Hyperplasia

losartan potassium (+) hydrochlorothiazide

Phase 3

Hypertension

SCH 900962 / Corifollitropin alfa / Org 36286

Phase 3

Infertility

MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 15 weeks

Phase 3

Osteoporosis

atorvastatin

Phase 3

Hypercholesterolemia

Tibolone 2.5 mg

Phase 3

Postmenopausal Women

MK0663, Etoricoxib / Duration of Treatment : 12 Weeks

Phase 3

Recurrent Low Back Pain

A-Phase: tirofiban; Z-Phase simvastatin

Phase 3

Acute Coronary Syndrome

MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet

Phase 3

Osteoporosis

Radiopaque Implanon

Phase 3

Contraception

MK-0653, ezetimibe

Phase 3

Hypercholesterolaemia

ezetimibe 10 mg

Phase 3

Hypercholesterolemia

losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])

Phase 3

Hypertension

NOMAC-E2

Phase 3

Contraception

olanzapine

Phase 3

Schizophrenia

MK0653, ezetimibe

Phase 3

Lipid Metabolism, Inborn Errors

Desloratadine (Clarinex)

Phase 3

Allergic Rhinitis

MK0476, montelukast sodium / Duration of Treatment: 1 Year

Phase 3

Asthma, Bronchial

tibolone

Phase 3

Sexual Dysfunction

Desloratadine 5 mg

Phase 3

Eczema

tapinarof cream, 1%

Phase 3

Plaque Psoriasis

phenylephrine

Phase 3

Rhinitis, Allergic, Seasonal

5-mg Desloratadine

Phase 3

Rhinitis, Allergic, Seasonal

asenapine

Phase 3

Schizophrenia

Mometasone Furoate Nasal Spray (MFNS)

Phase 3

Nasal Polyps

Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI

Phase 3

Asthma

MK0653, ezetimibe / Duration of Treatment: 6 Weeks

Phase 3

Hypercholesterolemia

MK0653, ezetimibe / Duration of Treatment: 30 Weeks

Phase 3

Diabetes Mellitus, Type 2

DRSP-EE

Phase 3

Contraception

Part I - etoricoxib 60 mg

Phase 3

Spondylitis, Ankylosing

Mometasone furoate/formoterol (MF/F) MDI

Phase 3

Asthma

Haloperidol

Phase 3

Schizophrenia

MK0663, etoricoxib

Phase 3

Rheumatoid Arthritis

FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)

Phase 3

Osteoporosis

Etoricoxib 90 mg

Phase 3

Pain, Postoperative

MK0653A (ezetimibe [+] simvastatin)

Phase 3

Hypercholesterolemia

Montelukast

Phase 3

Rhinitis, Allergic, Perennial

MK0217, /Duration of Treatment : 12 Months

Phase 3

Osteoporosis, Postmenopausal

desloratadine

Phase 3

Dermatitis, Atopic

MK0462, rizatriptan benzoate / Duration of Treatment: 1day

Phase 3

Migraine

Ezetimibe

Phase 3

Hypercholesterolemia

Radiopaque Etonogestrel Implant

Phase 3

Contraception

rizatriptan benzoate

Phase 3

Migraine Headache

Ezetimibe + Atorvastatin

Phase 3

Hypercholesterolemia

Tapinarof

Phase 3

Plaque Psoriasis

Montelukast 10 mg/loratadine 10 mg

Phase 3

Allergic Rhinitis

ezetimibe/simvastatin

Phase 3

Hypercholesterolemia

losartan potassium

Phase 3

Hypertension

MK0476, montelukast sodium / Duration of Treatment: 12 Weeks

Phase 3

Asthma

mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID

Phase 3

Asthma

Asenapine - Open Label

Phase 3

Schizophrenia

Simvastatin 20 mg

Phase 3

Hypercholesterolemia

ezetimibe with simvastatin

Phase 3

Hypercholesterolemia

Rizatriptan 5 mg

Phase 3

Migraine Disorders

SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )

Phase 3

Asthma

mometasone furoate combination MDI 200/10 mcg BID

Phase 3

Asthma

MK0663, etoricoxib / Duration of Treatment: 6 Weeks

Phase 3

Osteoarthritis

simvastatin (+) ezetimibe

Phase 3

Hypercholesterolemia

Montelukast Oral Granules (OG)

Phase 3

Perennial Allergic Rhinitis

Salmeterol xinafoate

Phase 3

Exercise Induced Asthma

MK0733 / Duration of Treatment: 18 Weeks

Phase 3

HDL Cholesterol

Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg

Phase 2

Asthma

Nomegestrol acetate (NOMAC)

Phase 2

Contraception

etoricoxib

Phase 2

Rheumatoid Arthritis

Desloratadine 2.5 mg

Phase 2

Post-nasal Drip

OG-6219

Phase 2

Endometriosis

etonogestrel with testosterone undecanoate

Phase 2

Contraception

Org 36286

Phase 2

Infertility

E6005 ointment (vehicle)

Phase 2

Atopic Dermatitis

Mometasone furoate

Phase 2

Rhinitis, Allergic, Perennial

Org 36286 (corifollitropin alfa)

Phase 2

In Vitro Fertilization

mometasone furoate/formoterol 100/10 mcg

Phase 2

Asthma

Ganirelix

Phase 2

Controlled Ovarian Stimulation

MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks)

Phase 2

Osteoarthritis

MK-0476, montelukast sodium

Phase 2

Bronchiolitis

Nomegestrol acetate contraceptive vaginal ring (NOMAC-CVR)

Phase 2

Dysmenorrhea

MFNS

Phase 2

Acute Rhinosinusitis

Etoricoxib 75 mg 4% DMSO Gel

Phase 2

Osteoarthritis Pain

E6005

Phase 2

Atopic Dermatitis

Market-Implied Move
Regulatory Approvals

Frequently asked questions

What is in Organon & Co.'s drug pipeline?

CatalystAlert tracks 98 drug candidates in Organon & Co.'s (OGN) pipeline across Phase 3, Phase 2. Its lead program is MK0217, alendronate sodium / Duration of Treatment : 2 Years (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Organon & Co.'s next FDA catalyst?

Organon & Co.'s (OGN) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track OGN biotech catalysts?

Add OGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Organon & Co.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply